Zobrazeno 1 - 10
of 42
pro vyhledávání: '"J. Michael Woolley"'
Publikováno v:
Kidney International Reports, Vol 3, Iss 2, Pp 385-393 (2018)
There are limited data on the cost of hyperkalemia. Methods: This retrospective analysis of the Truven MarketScan claims database assessed the economic burden of hyperkalemia among selected adult patients with hyperkalemia and matched controls. Resul
Externí odkaz:
https://doaj.org/article/6d625d0e5fb044d2a50315afcf5f9a95
Publikováno v:
Current Medical Research and Opinion. 34:971-978
The retrospective study aimed to estimate prevalence of hyperkalemia using a large US commercial claims database.Adults with serum potassium lab data (2010 to 2014) and ≥1 calendar year of data were included from a large US commercial claims databa
Autor:
Herbert L Bonkovsky, J Michael Woolley
Publikováno v:
Canadian Journal of Gastroenterology, Vol 14, Iss Suppl B, Pp 21B-30B (2000)
Externí odkaz:
https://doaj.org/article/2f365109c83f44fa9787427aa7829b46
Autor:
Ikuo Hirano, Kathryn A. Peterson, Joseph A. Murray, Emily Love, Sarah Ollis, Evan S. Dellon, Catherine Foley, Henrik S. Rasmussen, Benjamin Banderas, Alan L. Shields, J. Michael Woolley, Camilla Shaw
Publikováno v:
American Journal of Gastroenterology. 114:S694-S695
Autor:
Patrick W. Sullivan, Jon Campbell, Vahram Ghushchyan, Gary Globe, Jeff Lange, J Michael Woolley
Publikováno v:
Journal of Asthma. 52:669-680
Objectives: Little is known about the disposition of severe patients prior to treatment escalation. To classify patients by treatment step using pharmacy data and describe their economic and healthcare utilization, insurance status, and sociodemograp
Publikováno v:
American healthdrug benefits. 10(4)
Hyperkalemia (serum potassium5.0 mEq/L) may be caused by reduced kidney function and drugs affecting the renin-angiotensin-aldosterone system and is often present in patients with chronic kidney disease (CKD).To quantify the burden of hyperkalemia in
Autor:
Steven R. Cummings, Wendy S. Post, Xiaohui Li, Suzanne E. Judd, J. Wouter Jukema, James D. Stewart, Daniel S. Evans, Yongmei Liu, Yii-Der Ida Chen, Iris Postmus, L. Adrienne Cupples, J. Michael Woolley, Eric A. Whitsel, Tamara B. Harris, Kerri L. Wiggins, George Howard, Robert S. Rosenson, Adolfo Correa, Albert V. Smith, Paul Muntner, Fangui Sun, Bruce M. Psaty, Marguerite R. Irvin, Stella Trompet, Christy L. Avery, Mary Cushman, Emily B. Levitan, Monika M. Safford, Jerome I. Rotter, Vilmundur Gudnason, Shia T. Kent, Colleen M. Sitlani, Leslie A. Lange, James G. Wilson, Ramachandran S. Vasan
Publikováno v:
Circulation: Cardiovascular Genetics
Circulation: Cardiovascular Genetics, 10(4)
Circulation: Cardiovascular Genetics, 10(4)
Background— PCSK9 loss-of-function (LOF) variants allow for the examination of the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovascular events. We examined the association of PCSK9 LOF variants with LDL-C and in
Autor:
Monika M. Safford, Devin M. Mann, Rosenson Robert, Michael E. Farkouh, Christopher Gamboa, Stephen P. Glasser, Huifeng Yun, Emily B. Levitan, Paul Muntner, J. Michael Woolley
Publikováno v:
The American Journal of the Medical Sciences. 348:108-114
Statins reduce the risk of coronary heart disease (CHD) in individuals with a history of CHD or risk equivalents. A 10-year CHD risk20% is considered a risk equivalent but is frequently not detected. Statin use and low-density lipoprotein cholesterol
Autor:
J. Michael Woolley, Vera Bittner, Robert S. Rosenson, Pankaj Sharma, Meredith L. Kilgore, Paul Muntner
Publikováno v:
Journal of Clinical Lipidology. 8:86-93
Background Although low-density lipoprotein cholesterol (LDL-C) is recommended as the primary marker to guide lipid-lowering therapy, some data suggest non–high-density lipoprotein cholesterol (non–HDL-C) may better reflect coronary heart disease
Autor:
Hong Zhao, Pankaj Sharma, Paul Muntner, Stephen P. Glasser, Michael E. Farkouh, J. Michael Woolley, Vera Bittner, Emily B. Levitan, Todd M. Brown, Robert S. Rosenson, Meredith L. Kilgore, Huifeng Yun
Publikováno v:
The American Journal of Cardiology. 112:664-670
Marked increases in the awareness, treatment, and control of high low-density lipoprotein (LDL) cholesterol occurred among United States (US) adults from 1988-1994 to 1999-2004. An update to the Third Adult Treatment Panel guidelines was published in